

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Jaydess®
Indication under review	Contraception
Policy No:	APC 098
Date of Issue:	March 2015
Review Date:	March 2018
Policy Statement: Jaydess® is indicated for use as contraception only.	
Traffic Light Status	Green
Key Points considered: <ul style="list-style-type: none"> • Treatment with Jaydess® is for contraception alone unlike Mirena® which can also be used for menorrhagia. • Jaydess® is licensed for use for 3 years (Mirena® is 5 years) • The inserter tube is narrower and the overall frame is smaller, in theory making insertion of Jaydess® easier. • Studies are ongoing into the long term safety of Jaydess® including any associated links to ectopic pregnancies and this should be discussed with the patient. 	
References: <ul style="list-style-type: none"> • Faculty of Sexual & Reproductive Healthcare. New Product review from the clinical effectiveness unit. Jaydess® Levonorgestrel Intrauterine System (LNG-IUS). • NICE ESNM41: Long-acting reversible contraception:levonorgestrel 13.5mg intrauterine delivery system 	
Date taken to APC:	4 th March 2015
Date Ratified by MMC on Behalf of the Board:	18 th March 2015

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only